1fvtst callout
Pure Pain Relief
New Ethiqa XR™ gives you the Confidence of:
- The first and only Pharmaceutical Grade, extended-release buprenorphine
- FDA-indexed for use in mice and rats
- 1 dose = 72 hours of clinical analgesia
This formation for mice and rats is legally marked as an FDA-indexed product under MIF 900-014. Extra-label use is prohibited.
Please see Prescribing Information for additional Important Safety Information.
Important Safety Information
WARNING: ABUSE POTENTIAL, LIFE-THREATENING RESPIRATORY DEPRESSION, and ACCIDENTAL EXPOSURE
Abuse Potential
This formulation contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.
Do not dispense this formulation.
Life-Threatening Respiratory Depression
The concentration of buprenorphine is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of this formulation. There are additive CNS depressant efects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, this formulation should only be administered by a veterinarian or laboratory staf trained in the handling of potent opioids.
Innovators in Long-Acting Pain Management
We are committed to researching and developing new, innovative solutions for animal health.
Our team of experts in veterinary and human medicine have extensive experience in the commercialization of new pharmaceuticals.
Fidelis Pharmaceuticals is a proud member of AALAS and AVMA and supports the position that the appropriate use of pain management is a scientific and moral imperative. We are committed to the research and development of trusted, extended release, long-acting pain management products for laboratory animals.
Our Team
Michael Wells
Executive Chairman
Michael Wells serves as the Executive Chairman for Fidelis Pharmaceuticals. He has had a long and distinguished career as an entrepreneur and an investor in start-up healthcare companies. In addition to his role at Fidelis, he is also the founding Managing Director of Princeton Biopharma Capital Partners, a firm he created in 2010 for the purpose of providing growth capital to pharmaceutical and medical device companies. Prior to creating this company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases. For his part in creating and growing this company he was named an Ernst & Young Entrepreneur of the Year in 2009 and in 2010 the company was acquired by Valeant Pharmaceuticals for $330 million. Michael has played a role in the formation of five companies and frequently mentors aspiring entrepreneurs. His career began at Merck & Co. where he held a range of sales and marketing positions over eight years.
Michael holds a Bachelor of Science and a Master of Science from the University of Pittsburgh in addition to an MBA from The Wharton School. In addition to serving on the Fidelis board, his other board appointments include Covis Pharma Sarl, Valeo Pharmaceuticals, PhotoSonix Medical and he is a Trustee at the University of Pittsburgh.
Clay Wilson, MD, JD
EVP, Commercial Development
Clay Wilson, MD, JD, is the Executive Vice President for Business Development at Fidelis Pharmaceuticals. Clay is a seasoned medical industry executive. He is a physician by training, as well as a patent attorney. His business background includes securities analyst positions covering biotech and medical devices for Wall Street firms Needham and Smith Barney/Citigroup. Clay has held executive roles in business development at both Johnson&Johnson and Bristol-Myers, Squibb. He has also served as an investment banking advisor in the healthcare group at the accounting firm KPMG.
Steven Leary, DVM
Chief Medical Officer
Steven Leary, DVM, DACLAM, serves as Chief Medical Officer with Fidelis Pharmaceuticals. He received his DVM from Iowa State University and postdoctoral training in laboratory animal medicine and comparative pathology from Johns Hopkins University. Dr. Leary has 40 years’ experience, including serving as director at the University of Alabama at Birmingham and Washington University in St. Louis. He served on AAALAC Council, as President of ACLAM, and as chair of the AVMA Animal Welfare Committee and Panels on Euthanasia, Humane Slaughter, and Depopulation. He is past recipient of the ISU Stange Award, Charles River Prize, and AALAS Griffin and Nathan R. Brewer awards.
Eric Schreiber
Head of Marketing
Eric Schreiber is Head of Marketing for Fidelis Pharmaceuticals. Eric has broad animal health commercialization experience, having launched more than 20 brands in his career, including pain management products for small animals. He has worked for manufacturers Pfizer Animal Health and Wyeth Pharmaceuticals, as well as for ad agencies Saatchi & Saatchi and Ogilvy. Eric graduated from Bucknell University and did graduate work at University of Richmond and The Wharton School.
